Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2019 | 1 |
2021 | 1 |
2022 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Toxic PARP trapping upon cAMP-induced DNA damage reinstates the efficacy of endocrine therapy and CDK4/6 inhibitors in treatment-refractory ER+ breast cancer.
Nat Commun. 2023 Nov 2;14(1):6997. doi: 10.1038/s41467-023-42736-y.
Nat Commun. 2023.
PMID: 37914699
Free PMC article.
Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer.
Assidicky R, Tokat UM, Tarman IO, Saatci O, Ersan PG, Raza U, Ogul H, Riazalhosseini Y, Can T, Sahin O.
Assidicky R, et al. Among authors: ersan pg.
Breast Cancer Res Treat. 2022 Jun;193(2):331-348. doi: 10.1007/s10549-022-06569-5. Epub 2022 Mar 25.
Breast Cancer Res Treat. 2022.
PMID: 35338412
Free PMC article.
Item in Clipboard
TLR ligand loaded exosome mediated immunotherapy of established mammary Tumor in mice.
Yildirim M, Yildirim TC, Turay N, Bildik T, Ibibik B, Evcili I, Ersan PG, Tokat UM, Sahin O, Gursel I.
Yildirim M, et al. Among authors: ersan pg.
Immunol Lett. 2021 Nov;239:32-41. doi: 10.1016/j.imlet.2021.08.004. Epub 2021 Aug 18.
Immunol Lett. 2021.
PMID: 34418488
Item in Clipboard
Targeting LINC00152 activates cAMP/Ca2+/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer.
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Cetin M, Tokat UM, Gedik ME, Bal H, Sahin OS, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O.
Saatci O, et al. Among authors: ersan pg.
bioRxiv [Preprint]. 2023 Nov 5:2023.11.05.565697. doi: 10.1101/2023.11.05.565697.
bioRxiv. 2023.
PMID: 38496603
Free PMC article.
Preprint.
Item in Clipboard
Systems-level Analysis Reveals Multiple Modulators of Epithelial-mesenchymal Transition and Identifies DNAJB4 and CD81 as Novel Metastasis Inducers in Breast Cancer.
Uretmen Kagiali ZC, Sanal E, Karayel Ö, Polat AN, Saatci Ö, Ersan PG, Trappe K, Renard BY, Önder TT, Tuncbag N, Şahin Ö, Ozlu N.
Uretmen Kagiali ZC, et al. Among authors: ersan pg.
Mol Cell Proteomics. 2019 Sep;18(9):1756-1771. doi: 10.1074/mcp.RA119.001446. Epub 2019 Jun 20.
Mol Cell Proteomics. 2019.
PMID: 31221721
Free PMC article.
Item in Clipboard
The miR-644a/CTBP1/p53 axis suppresses drug resistance by simultaneous inhibition of cell survival and epithelial-mesenchymal transition in breast cancer.
Raza U, Saatci Ö, Uhlmann S, Ansari SA, Eyüpoğlu E, Yurdusev E, Mutlu M, Ersan PG, Altundağ MK, Zhang JD, Doğan HT, Güler G, Şahin Ö.
Raza U, et al. Among authors: ersan pg.
Oncotarget. 2016 Aug 2;7(31):49859-49877. doi: 10.18632/oncotarget.10489.
Oncotarget. 2016.
PMID: 27409664
Free PMC article.
Item in Clipboard
Cite
Cite